The combined abuse of cocaine and alcohol is a common occurrence. Epidemiological studies have shown that at least 62% of cocaine abusers and possibly up to 90% in some populations are concomitant alcohol abusers. Patterns of cocaine and alcohol use vary in individuals. The association between cocaine use and alcohol use and the successful treatment of alcoholism with disulfiram led us to hypothesize that disulfiram might be efficacious in the treatment of cocaine addiction, and cocaine addiction which is accompanied by alcohol abuse. Furthermore, above and beyond it's direct effect on alcohol consumption, disulfiram may potentiate serotonergic neurotransmission by inhibition of serotonin metabolism which may be important to diminishing cocaine- induced euphoria or to modulation of dysphoria associated with cocaine administration. The major aim of this project is to assess the potential efficacy of disulfiram as a treatment for cocaine addiction and cocaine addiction complicated by alcohol abuse and to examine possible mechanisms, especially the contribution of serotonergic neurotransmission to cocaine effects. We propose to explore this by conducting the following inpatient studies: 1. a pharmacologic challenge in which physiological and behavioral effects of cocaine in humans will be determined in a dose response in which several doses of cocaine and disulfiram are studied and 2. a pharmacologic challenge in which the acute effects of cocaine administration following chronic administration of disulfiram (using the best dose of disulfiram as determined in Study 1) are determined. These studies will include assessment of direct effects of disulfiram on cocaine metabolism to determine the potential for toxicity in humans. In Study 3 we will use cocaethylene as a pharmacologic probe in an attempt to determine the relative contribution of dopamine and serotonin to cocaine effects and to develop an understanding of possible mechanisms by which disulfiram may modify drug effects. Cocaethylene has been shown to have much greater selectivity for the dopamine transporter than does cocaine. As such, cocaethylene may be used as a tool to sort out the role of serotonin versus dopamine in mediating the actions of disulfiram on cocaine effects. The study consists of a pharmacologic challenge in which cocaethylene will be administered prior to and following chronic treatment with disulfiram. Cocaine will be used as a comparator. Study 4 consists of a pharmacologic challenge in which the behavioral, physiological, and pharmacokinetic effects of cocaine administration following chronic treatment with disulfiram is ascertained in subjects with chronic schizophrenia and cocaine or cocaine-alcohol abuse. This study is important to determination of efficacy and safety of disulfiram treatment for this high risk population.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
5P50DA009250-05
Application #
6104095
Study Section
Project Start
1998-09-30
Project End
1999-09-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
5
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Yale University
Department
Type
DUNS #
082359691
City
New Haven
State
CT
Country
United States
Zip Code
06520
Chawarski, Marek C; Fiellin, David A; O'Connor, Patrick G et al. (2007) Utility of sweat patch testing for drug use monitoring in outpatient treatment for opiate dependence. J Subst Abuse Treat 33:411-5
Chawarski, Marek C; Moody, David E; Pakes, Juliana et al. (2005) Buprenorphine tablet versus liquid: a clinical trial comparing plasma levels, efficacy, and symptoms. J Subst Abuse Treat 29:307-12
Kosten, Thomas R; Fiellin, David A; U.S. National Buprenorphine Implementation Program (2004) Buprenorphine for office-based practice: consensus conference overview. Am J Addict 13 Suppl 1:S1-7
Kosten, Thomas; Oliveto, Alison; Feingold, Alan et al. (2003) Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug Alcohol Depend 70:315-25
Sofuoglu, Mehmet; Gonzalez, Gerardo; Poling, James et al. (2003) Prediction of treatment outcome by baseline urine cocaine results and self-reported cocaine use for cocaine and opioid dependence. Am J Drug Alcohol Abuse 29:713-27
Kosten, Thomas; Poling, James; Oliveto, Alison (2003) Effects of reducing contingency management values on heroin and cocaine use for buprenorphine- and desipramine-treated patients. Addiction 98:665-71
Stine, Susan M; Southwick, Steven M; Petrakis, Ismene L et al. (2002) Yohimbine-induced withdrawal and anxiety symptoms in opioid-dependent patients. Biol Psychiatry 51:642-51
Stine, S M; Grillon, C G; Morgan 3rd, C A et al. (2001) Methadone patients exhibit increased startle and cortisol response after intravenous yohimbine. Psychopharmacology (Berl) 154:274-81
Jacobsen, L K; Southwick, S M; Kosten, T R (2001) Substance use disorders in patients with posttraumatic stress disorder: a review of the literature. Am J Psychiatry 158:1184-90
Gottschalk, C; Beauvais, J; Hart, R et al. (2001) Cognitive function and cerebral perfusion during cocaine abstinence. Am J Psychiatry 158:540-5

Showing the most recent 10 out of 39 publications